The 5 linked references in paper E. KROPACHEVA S., O. ZEMLYANSKAYA A., A. DOBROVOLSKY B., E. PANCHENKO P., Е. КРОПАЧЕВА С., О. ЗЕМЛЯНСКАЯ А., А. ДОБРОВОЛЬСКИЙ Б., Е. ПАНЧЕНКО П. (2017) “ЭФФЕКТИВНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ ВАРФАРИНОМ: ВЛИЯНИЕ НА ЧАСТОТУ ИШЕМИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ И КЛИНИЧЕСКИЕ ПРЕДИКТОРЫ ИХ РАЗВИТИЯ (результаты проспективного 10-летнего наблюдения) // THE EFFICACY OF LONG-TERM WARFARIN THERAPY: THE IMPACT ON THE INCIDENCE OF ISCHEMIC CEREBROVASCULAR DISORDERS AND CLINICAL PREDICTORS OF DEVELOPING SUCH DISORDERS. (Results of a prospective 10-year follow-up study)” / spz:neicon:aterotromboz:y:2017:i:2:p:115-130

  1. ESC Guidelines for the management of atrial fibrillation 2016. DOI: http://dx.doi.org/10.1093/eurheartj/ehw210 eh w210 First published online: 27 August 2016.
  2. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e637S–68S. doi: 10.1378/chest.11-2306. pmid:22315274.
  3. Arihiro S, Todo K, Koga M et al. Three-month riskbenefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke, 2016 Jul, 11(5): 565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
  4. Ba_aran Е, Dogan V, Biteker M et al. Guideline-adherent therapy for stroke prevention in atrial fibrillation in different health care settings: Results from RAMSES study. Eur J Intern Med, 2017 May, 40: 50-55. doi: 10.1016/j.ejim.2017.02.011. Epub 2017 Feb 24.
  5. Sullivan RM, Zhang J, Zamba G et al. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol,2012 Dec 15, 110(12): 1799-802. doi: 10.1016/j.amjcard.2012.08.014. Epub 2012 Sep 18.